Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012987 | 0.91 | CNR1 (0.47) | CNR1SCN2ASCN10ACNR2CXCR3 | |
| SCHEMBL4013997 | 0.90 | CNR1 (0.49) | CNR1SCN2ASCN10ACNR2CXCR3 | |
| SCHEMBL4162485 | 0.89 | CNR1 (0.48) | CNR1CNR2CXCR3 | |
| SCHEMBL4168753 | 0.87 | CNR1 (0.48) | CNR1CNR2CXCR3 | |
| SCHEMBL3924890 | 0.83 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL3915821 | 0.83 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL4014970 | 0.81 | CNR1 (0.51) | CNR1CNR2 | |
| SCHEMBL4011940 | 0.80 | CNR1 (0.50) | CNR1CNR2 | |
| SCHEMBL4012691 | 0.80 | CNR1 (0.54) | CNR1SCN2ASCN10ACNR2 | |
| SCHEMBL4014934 | 0.79 | CNR1 (0.51) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008040651-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |